University of Science and Technology of China, Chinese Society for Immunology, Nature Immunology, Nature Reviews Immunology, and Cellular & Molecular Immunology are pleased to present:

Grand Challenges in Immunology: Immunotherapy for Cancer and Beyond

June 11-13 , 2019
Wyndham Grand Qingdao, China

Immunotherapy is changing the treatment paradigm for many types of cancer, with a number of checkpoint blockers and the first cellular therapies on the market. Beyond cancer, immunotherapeutic approaches are undergoing clinical trials for autoimmune conditions and infectious diseases. This Nature conference brings together leading experts from around the globe to discuss a range of immunotherapeutic approaches and the immunological basis that informs these efforts. Besides covering immune checkpoint inhibitors and cellular therapies, sessions will explore vaccination approaches and oncolytic therapy, the role of innate immune cells and their potential for immunotherapy, the effect of the microbiota on immunotherapy and how to exploit immunometabolism to modulate immune responses in cancer and beyond.



The abstract submission deadline is May 15, 2019 at 6:00 p.m. EST.

Conference hashtag: #ICB19
Twitter: @NatureConf, @NatureImmunology , @NatureReviewsImmunology

Grand Challenges in Immunology: Immunotherapy for Cancer and Beyond

  • Scientific Committee

    • Zhigang Tian (University of Science and Technology of China, China)
    • Xuetao Cao (Nankai University, China)
    • Jeff Pollard (University of Edinburgh, UK)
    • Arlene Sharpe (Harvard Medical School, USA)
    • Yvonne Bordon (Nature Reviews Immunology, UK)
    • Zoltan Fehervari (Nature Immunology, UK)
    • Alexandra Flemming (Nature Reviews Immunology, UK)
    • Kirsty Minton (Nature Reviews Immunology, UK)

  • Date

    June 11-13, 2019

  • Venue

    Wyndham Grand Qingdao, China